GURUFOCUS.COM » STOCK LIST » USA » NAS » OncoCyte Corp (NAS:OCX) » Definitions » Short-Term Debt
Switch to:

OncoCyte (NAS:OCX) Short-Term Debt

: $0.00 Mil (As of Sep. 2022)
View and export this data going back to 2015. Start your Free Trial

OncoCyte's Short-Term Debt for the quarter that ended in Sep. 2022 was $0.00 Mil.

OncoCyte's quarterly Short-Term Debt declined from Mar. 2022 ($0.95 Mil) to Jun. 2022 ($0.57 Mil) and declined from Jun. 2022 ($0.57 Mil) to Sep. 2022 ($0.00 Mil).

OncoCyte's annual Short-Term Debt increased from Dec. 2019 ($1.13 Mil) to Dec. 2020 ($2.39 Mil) but then declined from Dec. 2020 ($2.39 Mil) to Dec. 2021 ($1.31 Mil).


OncoCyte Short-Term Debt Historical Data

The historical data trend for OncoCyte's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoCyte Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Short-Term Debt
Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.80 0.80 1.13 2.39 1.31

OncoCyte Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Short-Term Debt Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.50 1.31 0.95 0.57 -

OncoCyte Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


OncoCyte Short-Term Debt Related Terms

Thank you for viewing the detailed overview of OncoCyte's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


OncoCyte (NAS:OCX) Business Description

OncoCyte logo
Traded in Other Exchanges
Address
15 Cushing, Irvine, CA, USA, 92618
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through the United States, and it earns revenue from the sale of diagnostic tests.
Executives
Josh Riggs officer: Interim CEO 15 CUSHING, IRVINE CA 92618
Lou Silverman director
James Yang Liu officer: Controller, PAO C/O ONCOCYTE CORPORATION, 15 CUSHING, IRVINE CA 92618
John Peter Gutfreund director C/O ONCOCYTE CORPORATION, 15 CUSHING, IRVINE CA 92618
Anish M. John officer: SVP, Finance, and Interim CFO C/O ONCOCYTE CORPORATION,, 15 CUSHING, IRVINE CA 92618
Pura Vida Investments, Llc 10 percent owner 512 W 22ND STREET, 7TH FLOOR, NEW YORK NY 10011
Efrem Kamen 10 percent owner C/O PURA VIDA INVESTMENTS, LLC, 512 W 22ND STREET, 7TH FLOOR, NEW YORK NY 10011
Gisela Paulsen officer: Chief Operating Officer 5505 ENDEAVOR LANE, MADISON WI 53719
Li Yu officer: VP Cntrllr/Prncpl Acctng Offcr 120 NEWPORT CENTER DRIVE., NEWPORT BEACH CA 92660
Jennifer L. Carter director C/O DFP SPONSOR LLC, 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Douglas T. Ross officer: Chief Medical Officer 15 CUSHING, IRVINE CA 92618
Tony T Kalajian officer: SVP-Chief Accounting Officer 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Melinda Griffith director 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Padma Sundar officer: SVP, Marketing & Market Access 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Ronald Asbury Andrews director 5791 VAN ALLEN WAY, CARLSBAD CA 92008

OncoCyte (NAS:OCX) Headlines